C8 Health Study Links AI Platform to Lower Infection Risk and Cost Savings in Surgery

New updates have been reported about C8 Health.

C8 Health is reporting new real-world data showing its AI-driven best-practice implementation platform materially improves adherence to perioperative glucose management (PGM) protocols, a critical driver of surgical site infection (SSI) rates and costs. In a prospective observational study at The University of Texas Medical Branch, clinicians using C8’s system achieved an approximate 20% absolute increase in PGM compliance over non-users, contributing to a 9.1% absolute compliance gain across the department over three months.

Those gains translate into an estimated $773,000 in projected annual savings from reduced SSIs, underscoring the financial value proposition of C8 Health’s technology for hospitals under margin pressure and value-based care models. The platform combines individualized, AI-generated performance feedback with institution-approved clinical guidance at the point of care, delivered through in-app dashboards, trend summaries, and targeted notifications that benchmark each clinician against prior performance and departmental goals.

C8 Health’s co-founder and chief medical officer, Dr. Ido Zamberg, framed the findings as evidence that health systems can move beyond passive measurement and actually operationalize evidence-based practices at scale without adding administrative burden. By embedding guidance into clinicians’ workflow and making adherence visible and actionable, the company aims to tackle the long-standing execution gap between known quality protocols and day-to-day practice. Study co-author Dr. Brian Masel of UTMB highlighted that the platform helped clinicians manage increasingly complex perioperative protocols more reliably, suggesting broader applicability beyond glucose management.

For C8 Health, the results presented at the Society for Perioperative Assessment and Quality Improvement (SPAQI) strengthen its clinical and economic case with prospective, real-world data from an academic medical center. The performance outcomes can support commercialization by appealing to hospital executives seeking measurable quality improvements and cost reductions, and may help the company secure additional pilots, longer-term contracts, or strategic partnerships. The study is ongoing, and further data could expand the evidence base for the platform across additional quality measures, influencing C8 Health’s growth trajectory and competitive positioning in AI-enabled clinical performance tools.